AU2023231285A1 - Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19 - Google Patents

Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19 Download PDF

Info

Publication number
AU2023231285A1
AU2023231285A1 AU2023231285A AU2023231285A AU2023231285A1 AU 2023231285 A1 AU2023231285 A1 AU 2023231285A1 AU 2023231285 A AU2023231285 A AU 2023231285A AU 2023231285 A AU2023231285 A AU 2023231285A AU 2023231285 A1 AU2023231285 A1 AU 2023231285A1
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
protein
seq
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023231285A
Other languages
English (en)
Inventor
Adolfo Garcia-Sastre
Irene GONZALEZ DOMINGUEZ
Florian KRAMMER
Peter Palese
Weina SUN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of AU2023231285A1 publication Critical patent/AU2023231285A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2023231285A 2022-03-10 2023-03-09 Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19 Pending AU2023231285A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263318640P 2022-03-10 2022-03-10
US63/318,640 2022-03-10
PCT/US2023/064063 WO2023173032A2 (en) 2022-03-10 2023-03-09 Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19

Publications (1)

Publication Number Publication Date
AU2023231285A1 true AU2023231285A1 (en) 2024-07-25

Family

ID=87936013

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023231285A Pending AU2023231285A1 (en) 2022-03-10 2023-03-09 Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19

Country Status (11)

Country Link
US (1) US20250186578A1 (https=)
EP (1) EP4489779A2 (https=)
JP (1) JP2025509352A (https=)
KR (1) KR20240161963A (https=)
CN (1) CN119317446A (https=)
AU (1) AU2023231285A1 (https=)
CA (1) CA3245533A1 (https=)
CL (1) CL2024002683A1 (https=)
CO (1) CO2024012344A2 (https=)
MX (1) MX2024011049A (https=)
WO (1) WO2023173032A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2251034T3 (pl) * 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
MX2022013934A (es) * 2020-05-07 2023-02-22 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo.
US20250041402A1 (en) * 2021-09-30 2025-02-06 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof

Also Published As

Publication number Publication date
CN119317446A (zh) 2025-01-14
EP4489779A2 (en) 2025-01-15
JP2025509352A (ja) 2025-04-11
US20250186578A1 (en) 2025-06-12
CA3245533A1 (en) 2023-09-14
KR20240161963A (ko) 2024-11-13
MX2024011049A (es) 2024-09-18
WO2023173032A2 (en) 2023-09-14
CO2024012344A2 (es) 2024-12-30
CL2024002683A1 (es) 2025-01-03
WO2023173032A3 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
CN111088283B (zh) mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
US11542527B2 (en) Parainfluenza virus 5 based vaccines
US9701723B2 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
ES2929942T3 (es) Vacunas contra el virus de la gripe y sus usos
JP2023524990A (ja) ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用
US20250041402A1 (en) Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof
Demminger et al. Adeno‐associated virus‐vectored influenza vaccine elicits neutralizing and Fcγ receptor‐activating antibodies
US20250228929A1 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
CN117098551A (zh) 编码截短的ns1蛋白和sars-cov受体结合域的流感病毒
US20250186578A1 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19
US20240199705A1 (en) Chimeric newcastle disease virus expressing apmv hn and f proteins
US20250250304A1 (en) Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof